Company Profile

Salix Pharmaceuticals Ltd (AKA: Salix Pharmaceuticals Inc)
Profile last edited on: 9/11/2015      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

8510 Colonnade Center Drive
Raleigh, NC 27615
   (919) 862-1000
Location: Multiple
Congr. District: 04
County: Wake

Public Profile

With facilities in California and North Carolina, Salix Pharmaceuticals, Ltd. is specialty pharmaceutical company engaged in acquiring, developing, and commercializing prescription drugs for the treatment of gastrointestinal disorders . The firm was acquired by Valeant Pharma in early 2015. Salix’s products include XIFAXAN tablet, a gastrointestinal-specific oral antibiotic for the treatment of patients with travelers’ diarrhea; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; APRISO for the maintenance of remission of ulcerative colitis in adults; MOVIPREP and OSMOPREP, which are used for cleansing of the colon as a preparation for colonoscopy in adults; METOZOLV ODT that orally disintegrating tablets used as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease. Its products also include AZASAN, which is used as an adjunct for the prevention of rejection in renal homotransplantations, and for the management of active rheumatoid arthritis to reduce signs and symptoms; VISICOL tablets for cleansing of the colon as a preparation for colonoscopy; and ANUSOL-HC and PROCTOCORT for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis, as an adjunct in the treatment of chronic Ulcerative Colitis, cryptitis, and other inflammatory conditions of the anorectum and pruritis ani. In addition, the company provides DIURIL for the treatment of high blood pressure and also as adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. Further, it has various product candidates under development for the treatment of irritable bowel syndrome, HIV-associated diarrhea, ulcerative colitis, and ulcerative proctitis, and Opioid induced constipation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1994 1 NIH $75,000
Project Title: Colon cancer chemoprevention by balsalazide & metabolite

Key People / Management

  Carolyn J Logan -- President and Chief Executive Officer

  Randy W Hamilton -- Founder and Business Development Advisor

  Lorin K Johnson -- Founder and Chief Scientific Liaison